Robust design in model-based analysis of longitudinal clinical data

Similar documents
Evaluation of the Fisher information matrix in nonlinear mixed eect models without linearization

F. Combes (1,2,3) S. Retout (2), N. Frey (2) and F. Mentré (1) PODE 2012

DESIGN EVALUATION AND OPTIMISATION IN CROSSOVER PHARMACOKINETIC STUDIES ANALYSED BY NONLINEAR MIXED EFFECTS MODELS

Sebastian Ueckert, France Mentré. To cite this version: HAL Id: inserm

Evaluation of the Fisher information matrix in nonlinear mixed effect models using adaptive Gaussian quadrature

Stochastic approximation EM algorithm in nonlinear mixed effects model for viral load decrease during anti-hiv treatment

An Approach for Identifiability of Population Pharmacokinetic-Pharmacodynamic Models

Population Design in Nonlinear Mixed Effects Multiple Response Models: extension of PFIM and evaluation by simulation with NONMEM and MONOLIX

OPTIMAL DESIGN FOR POPULATION PK/PD MODELS. 1. Introduction

An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments

Estimation and Model Selection in Mixed Effects Models Part I. Adeline Samson 1

Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effects Panhard Xavière

Generalizing the MCPMod methodology beyond normal, independent data

Description of UseCase models in MDL

Handling parameter constraints in complex/mechanistic population pharmacokinetic models

Correction of the likelihood function as an alternative for imputing missing covariates. Wojciech Krzyzanski and An Vermeulen PAGE 2017 Budapest

Modelling a complex input process in a population pharmacokinetic analysis: example of mavoglurant oral absorption in healthy subjects

Design of preclinical combination studies

Heterogeneous shedding of influenza by human subjects and. its implications for epidemiology and control

Sensitivity study of dose-finding methods

Generalizing the MCPMod methodology beyond normal, independent data

Extension of the SAEM algorithm for nonlinear mixed. models with two levels of random effects

Approximate analysis of covariance in trials in rare diseases, in particular rare cancers

A Clinical Trial Simulation System, Its Applications, and Future Challenges. Peter Westfall, Texas Tech University Kuenhi Tsai, Merck Research Lab

Comparison of multiple imputation methods for systematically and sporadically missing multilevel data

Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: application to HIV dynamics model

Design of HIV Dynamic Experiments: A Case Study

A comparison of estimation methods in nonlinear mixed effects models using a blind analysis

Improved conditional approximations of the population Fisher Information Matrix

Randomized dose-escalation design for drug combination cancer trials with immunotherapy

Approximation of the Fisher information and design in nonlinear mixed effects models

Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixedeffects

Pharmacometrics : Nonlinear mixed effect models in Statistics. Department of Statistics Ewha Womans University Eun-Kyung Lee

1Non Linear mixed effects ordinary differential equations models. M. Prague - SISTM - NLME-ODE September 27,

Improving a safety of the Continual Reassessment Method via a modified allocation rule

Efficient algorithms for calculating optimal designs in pharmacokinetics and dose finding studies

Integration of SAS and NONMEM for Automation of Population Pharmacokinetic/Pharmacodynamic Modeling on UNIX systems

Joint modeling of longitudinal and repeated time-to-event data using nonlinear mixed-effects models and the SAEM algorithm

Group sequential designs with negative binomial data

Hierarchical expectation propagation for Bayesian aggregation of average data

AP-Optimum Designs for Minimizing the Average Variance and Probability-Based Optimality

Optimal Adaptive Designs for Dose Finding in Early Phase Clinical Trials

Compound Optimal Designs for Percentile Estimation in Dose-Response Models with Restricted Design Intervals

Personalized Treatment Selection Based on Randomized Clinical Trials. Tianxi Cai Department of Biostatistics Harvard School of Public Health

Web-based Supplementary Material for A Two-Part Joint. Model for the Analysis of Survival and Longitudinal Binary. Data with excess Zeros

Practical issues related to the use of biomarkers in a seamless Phase II/III design

Nonlinear Mixed Effects Models

Uncertainty quantification and visualization for functional random variables

Research Article. Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method s Sensitivity to η-shrinkage

Confidence and Prediction Intervals for Pharmacometric Models

Interim Monitoring of Clinical Trials: Decision Theory, Dynamic Programming. and Optimal Stopping

RANDOMIZATIONN METHODS THAT

3 Results. Part I. 3.1 Base/primary model

Optimal input design for nonlinear dynamical systems: a graph-theory approach

Optimization Tools in an Uncertain Environment

A weighted differential entropy based approach for dose-escalation trials

Optimising Group Sequential Designs. Decision Theory, Dynamic Programming. and Optimal Stopping

Case Study in the Use of Bayesian Hierarchical Modeling and Simulation for Design and Analysis of a Clinical Trial

THE IMPORTANCE OF THE SIMULATION EXPECTATION AS A GOODNESS OF FIT DIAGNOSTIC FOR CATEGORICAL POPULATION PHARMACODYNAMIC MODELS

On Assessing Bioequivalence and Interchangeability between Generics Based on Indirect Comparisons

Type I error rate control in adaptive designs for confirmatory clinical trials with treatment selection at interim

A Note on Cochran Test for Homogeneity in Two Ways ANOVA and Meta-Analysis

STA 4273H: Statistical Machine Learning

BACKGROUNDS. Two Models of Deformable Body. Distinct Element Method (DEM)

Bayesian variable selection and classification with control of predictive values

Accurate Maximum Likelihood Estimation for Parametric Population Analysis. Bob Leary UCSD/SDSC and LAPK, USC School of Medicine

STUDY OF THE APPLICABILTY OF CONTENT UNIFORMITY AND DISSOLUTION VARIATION TEST ON ROPINIROLE HYDROCHLORIDE TABLETS

Checking model assumptions with regression diagnostics

Randomized Quasi-Monte Carlo for MCMC

Prerequisite: STATS 7 or STATS 8 or AP90 or (STATS 120A and STATS 120B and STATS 120C). AP90 with a minimum score of 3

Computer Vision Group Prof. Daniel Cremers. 10a. Markov Chain Monte Carlo

Fitting Complex PK/PD Models with Stan

BIOSTATISTICAL METHODS

ASME 2013 IDETC/CIE 2013 Paper number: DETC A DESIGN ORIENTED RELIABILITY METHODOLOGY FOR FATIGUE LIFE UNDER STOCHASTIC LOADINGS

Uncertainty Propagation

Optimal Designs for Some Selected Nonlinear Models

SAEMIX, an R version of the SAEM algorithm for parameter estimation in nonlinear mixed effect models

Practice of SAS Logistic Regression on Binary Pharmacodynamic Data Problems and Solutions. Alan J Xiao, Cognigen Corporation, Buffalo NY

A comparison of different Bayesian design criteria to compute efficient conjoint choice experiments

Sample Size Calculations for Group Randomized Trials with Unequal Sample Sizes through Monte Carlo Simulations

ADAPTIVE EXPERIMENTAL DESIGNS. Maciej Patan and Barbara Bogacka. University of Zielona Góra, Poland and Queen Mary, University of London

Chapter 4 Multi-factor Treatment Designs with Multiple Error Terms 93

Implementing Response-Adaptive Randomization in Multi-Armed Survival Trials

Mixture modelling of recurrent event times with long-term survivors: Analysis of Hutterite birth intervals. John W. Mac McDonald & Alessandro Rosina

On the efficiency of two-stage adaptive designs

Predicting the Onset of Nonlinear Pharmacokinetics

Bayesian Estimation of Input Output Tables for Russia

Introduction to Crossover Trials

1. Describing patient variability, 2. Minimizing patient variability, 3. Describing and Minimizing Intraindividual

Test Strategies for Experiments with a Binary Response and Single Stress Factor Best Practice

Use of frequentist and Bayesian approaches for extrapolating from adult efficacy data to design and interpret confirmatory trials in children

Latent Variable Model for Weight Gain Prevention Data with Informative Intermittent Missingness

A NOVEL OPTIMAL PROBABILITY DENSITY FUNCTION TRACKING FILTER DESIGN 1

Estimating functional uncertainty using polynomial chaos and adjoint equations

Influence of covariate distribution on the predictive performance of pharmacokinetic models in paediatric research

Score test for random changepoint in a mixed model

Estimation, Model Selection and Optimal Design in Mixed Eects Models Applications to pharmacometrics. Marc Lavielle 1. Cemracs CIRM logo

ML estimation: Random-intercepts logistic model. and z

Solving the steady state diffusion equation with uncertainty Final Presentation

How Critical is the Duration of the Sampling Scheme for the Determination of Half-Life, Characterization of Exposure and Assessment of Bioequivalence?

Transcription:

Robust design in model-based analysis of longitudinal clinical data Giulia Lestini, Sebastian Ueckert, France Mentré IAME UMR 1137, INSERM, University Paris Diderot, France PODE, June 0 016

Context Optimal design in Nonlinear Mixed Effects Models (NLMEM) Choosing a good design for a planned study is essential Number of subjects Number of sampling times for each subject Sampling times (allocation in time) Optimal design depends on prior information (model and parameters) Adaptive design Robust design (robustness on parameters) Atkinson, Optimum Experimental Designs. 1995 Dodds, Hooker and Vicini, J Pharmacokinet Pharmacodyn. 005 Foo L-K, Duffull S. J Biopharm Stat. 010

Objectives Objectives To compare various robust design criteria in NLMEM for two examples: Pharmacokinetic/Pharmacodynamic (PKPD) model with continuous data Longitudinal binary model using a new method for the evaluation of the Fisher information matrix (FIM) for NLMEM with discrete data 3

Method Basic mixed effect model Individual model (one continuous response) y i =f(φ i, ξ i ) + ε i vector of n i observations ξ i : individual sampling times t ij j=1, n i φ i : individual parameters (size p) f: nonlinear function defining the structural model ε i : gaussian zero mean random error var (ε i ) = diag (σ inter + σ slope f(φ i,ξ i )) combined error model Random-effects model φ i = μ exp(b i ) or μ + b i b i ~N 0, Ω here Ω diagonal: ω k = Var(b ik ) Population parameters: Ψ (size P) μ (fixed effects) unknowns in Ω (variance of random effects) σ inter and/or σ slope (error model parameters) 4

Method Basic population design Assumption N individuals i same elementary design ξ in all N subjects (ξ i = ξ) with t 1,, t n sampling times n tot = N n Population design Ξ = ξ, N 5

Method Fisher Information Matrix (FIM) in NLMEM Elementary FIM: M F Ψ, ξ = E L(y;Ψ) Ψ Ψ T No analytical expression for FIM Continuous data FO approximation o M F is implemented in the R function «PFIM» 1 Discrete data New method: Adaptive Gaussian Quadrature (AGQ) and Quasi Random Monte Carlo,3 (QRMC) o M F is implemented in an R program. Population FIM for one group design M F Ψ, Ξ = N M F Ψ, ξ Standard D- criterion: M F Ψ, Ξ 1/P where Ψ = Ψ (fixed values) 1 www.pfim.biostat.fr Ueckert S, Mentré F. Computational and Methodological Statistics (CMStatistics). 015 3 Ueckert S, Mentré F. Population Optimum Design of Experiments (PODE). 015 6

Method Criteria for optimal robust designs For robust design, a distribution for Ψ, p Ψ, is assumed Optimal robust designs ξ DE ξ ED ξ EID ξ ELD ξ MM = argmax ξ Criteria E Ψ M F Ψ, ξ E Ψ M F Ψ, ξ E Ψ M F Ψ, ξ E Ψ log M F Ψ, ξ min Ψ M F Ψ, ξ 1 1 7

Method Criteria for robust optimal designs Criteria are computed by Monte Carlo simulations (MC) K= Total number of MC samples Ψ 1... Ψ k... Ψ K M F Ψ 1, ξ... M F Ψ k, ξ... M F Ψ K, ξ Compute Robust Criteria 8

Outline Part I Part Comparison of robust design criteria in NLMEM with continuous data Designs were evaluated using (i) D-criterion and predicted Relative Standard Errors (RSE) (ii) Relative Root Mean Squared Errors (RRMSE) derived from Clinical Trial Simulations (CTS) Comparison of robust design criteria in NLMEM with discrete data (NEW way to compute FIM) Designs were evaluated using (i) D-criterion and predicted Relative Standard Errors (RSE) 9

Objectives Objectives To compare various robust design criteria in NLMEM for Pharmacokinetic/Pharmacodynamic (PKPD) model with continuous data 10

Method Part I - Example: PKPD model with continuous data responses model, for a biomarker in oncology (TGF β) PK: concentration f PK (φ, t) = DOSE V k = CL V k a k a k e kt e k at, ka Concentration CL/V Parameters: k a, V, CL PD: relative inhibition of TGF-β df PD (φ, t) dt = k out I max f PK (φ, t) f PK (φ, t)+ic 50 k out f PD (φ, t), ksyn Effect kout I max = 1 Parameters: k out, IC 50 The model is implemented in the DDMoRe model repository Gueorguieva et al., Comput Methods Programs Biomed. 007 Bueno et al., Eur J Cancer. 008 Gueorguieva et al., Br J Clin Pharmacol. 014 Lestini et al., Pharm Res. 015 11

Method Part I - Example: PKPD model with continuous data PK Parameters Ψ* p(ψ) μ ka h 1 μ V L 100 100 μ CL Lh 1 10 10 ω V 0.49 0.49 ω CL 0.49 0.49 σ slope,pk 0. 0. PD Parameters Ψ* p(ψ) μ kout h 1 0. logn log(0.), 0.8 μ IC50 mg/l 0.3 logn log(0.3), 0.8 ω kout 0.49 0.49 0.49 0.49 ω IC50 σ inter,pd 0. 0. 1

Method For each optimal design, and for a fixed equispaced design ξ ES compute D-criterion 13 and predicted RSE(%) for each set simulated parameters Ψ k, k = 1,.., K Design optimization Constraints N = 50 patients n = 3 observations per patient For PK, times fixed to 0.1, 4, 1 h For PD, 3 sampling times among possible times: 1,, 3, 4, 6, 9,10,15,, 3, 4 h 11 3 = 165 elementary designs FIM Computation FIM was computed in PFIM with FO approximation Optimization Find the D-optimal design ξ D using D-criterion for Ψ* Find optimal robust designs ξ DE, ξ ED, ξ EID, ξ ELD, ξ MM using MC with K=1000 Evaluation

Results D-criterion for optimal designs Robust designs Non-Robust designs Best design with highest median: ξ ELD 6 9 4 6 3 4 1 4 15 3 9 4 1 3 15 4 6 1 10 4 Whiskers of boxplot: 10 th and 90 th percentiles 14

Results Predicted Relative Standard Errors (RSE) μ kout μ IC 50 Robust designs Non-Robust designs Whiskers of boxplot: 10 th and 90 th percentiles 15

Results Predicted Relative Standard Errors (RSE) ω k out ω IC 50 Robust designs Non-Robust designs Whiskers of boxplot: 10 th and 90 th percentiles 16

Method Simulation Study For each design ξ Ψ 1 Y 1 Ψ 1... Ψ k... K=1000 Simulations N=50 subjects... Y k...... Ψ k... Compute Relative Root Mean Squared Error (RRMSE) Ψ K Y K Ψ K ξ = ξ DE, ξ ED, ξ EID, ξ ELD, ξ MM, ξ D, ξ ES Parameter estimation: SAEM algorithm in MONOLIX 4.3 5 chains, initial estimates: Ψ* 17

Results Relative Root Mean Squared Errors (RRMSE) = Means across parameters of RRMSEs standardized to ξ ELD RRMSEs 18

Conclusion Conclusion (Part 1) All criteria led to various designs rather different ξ ELD performed globally the best in terms of median of D-criteria across the 1000 MC simulations RRMSE obtained from the CTS study confirm the results, showing ξ ELD being globally the more robust design of the 1000 simulations 19

Objectives Objectives To compare various robust design criteria in NLMEM for Longitudinal binary model using a new method for the evaluation of the Fisher information matrix (FIM) for NLMEM with discrete data 0

Method Part - Example: NLMEM with binary data Logistic model for repeated binary response with treatment increasing the slope of the logit of the response with time logit π = β 1 + β (1 + μ 3 δ)t where β = g μ, b = μ + b; π is the probability of success treatment groups (δ = 0 & δ = 1) Parameters Ψ* p(ψ) μ 1 - - μ (months) 0.09 N 0.09, 0. μ 3 5 N 5, 0.49 0.49 ω (months) 0.3 0.3 ω 1 Ogungbenro K, Aarons L.. J Pharmacokinet Pharmacodyn. 011 Ueckert S, Mentré F. Computational and Methodological Statistics (CMStatistics). 015 1

Method Design optimization Constraints N = N T (treatment) + N C (control) = 100 patients n = 4 observations per patient including 0 and 1 months Possible intermediate times: 1,, 3, 4, 5, 6, 7, 8, 9, 10, 11 months 11 = 55 elementary designs (first and last times are fixed) FIM Computation o FIM was computed with the new method by Ueckert and Mentré, 015, based on AGQ and QRMC, with 3 nodes and 500 integrations samples Optimization Find the D-optimal design ξ D using D-criterion for Ψ* Find optimal robust designs ξ DE, ξ ED, ξ EID, ξ ELD, ξ MM using MC with K=1000 Evaluation For each optimal design, and for a fixed equispaced design ξ ES compute D- criterion and predicted RSE(%) for each set simulated parameters Ψ k, k = 1,.., K

Results D-criterion distribution for selected designs Robust designs Non-Robust designs Best designs with highest median: ξ EID and ξ ELD Whiskers of boxplot: 10 th and 90 th percentiles 0 7 1 0 7 1 0 1 1 0 1 3 1 0 3 8 1 0 3 1 0 4 8 1 3

Results Predicted Relative Standard Errors (RSE) Robust designs Non-Robust designs μ 1 μ μ 3 Whiskers of boxplot: 10 th and 90 th percentiles 4

Results Predicted Relative Standard Errors (RSE) ω 1 ω Robust designs Non-Robust designs Whiskers of boxplot: 10 th and 90 th percentiles 5

Conclusion Conclusion (Part ) The evaluation of FIM with the new approach is rather fast, allowing for the first time robust design optimization for discrete longitudinal models From median of 1000 simulated D-criteria, ξ ELD and ξ EID performed globally the best ξ ES has efficiency of 0.8 compare to ξ D. When prior uncertainty is assumed, the efficiency is 0.66 compared to ξ ELD 6

Conclusion General conclusions All these robust criteria were never systematically compared in NLMEM Different criteria led to various optimal designs, with different impact on predicted RSE From median of 1000 simulated D-criteria For PKPD model: ELD led to the best designs For longitudinal binary model: ELD and EID led to the best designs (which are very close) Perspectives Perform CTS for binary data example (Part ) Perform robust and adaptive design Perform model averaging 7

Thank You! Thank you for your attention! The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n 115156, resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/007-013) and EFPIA companies in kind contribution. The DDMoRe project is also financially supported by contributions from Academic and SME partners 8

Back-up 9

Method Criteria for robust optimal designs For robust design, a distribution for Ψ, p Ψ, is assumed Optimal designs Criteria Compute Criteria ξ DE E Ψ M F Ψ, ξ 1 K K k=1 M F Ψ k, ξ 1 K ξ ED E Ψ M F Ψ, ξ K M F Ψ k, ξ k=1 = argmax ξ EID ξ E Ψ M F Ψ, ξ 1 1 1 K K M F Ψ k, ξ 1 k=1 ξ ELD E Ψ log M F Ψ, ξ 1 K K log M F Ψ k, ξ k=1 ξ MM min Ψ M F Ψ, ξ min k(k=1, K) M F Ψ k, ξ 1 30